Treatment of Refractory Syndrome of Inappropriate Antidiuresis With Sodium-Glucose Cotransporter-2 Inhibitor
Abstract
Background/objective: The objective of this report is to describe a patient with syndrome of inappropriate antidiuresis (SIAD) who was successfully treated with empagliflozin monotherapy.
Case report: A 67-year-old man with a history of squamous cell carcinoma of the larynx and hypothyroidism was evaluated for persistent hyponatremia and diagnosed with SIAD. His serum sodium level remained below 130 mEq/L despite conventional therapy, including fluid restriction, furosemide, and sodium chloride tablets. He did not tolerate urea. Empagliflozin was added to his regimen resulting in improvement of serum sodium. Over time, furosemide was tapered and discontinued, followed by cessation of sodium chloride tablets. His serum sodium level normalized and remained stable on empagliflozin monotherapy without adverse effects.
Discussion: Empagliflozin, a sodium-glucose cotransporter-2 inhibitor exerts its diuretic effects through inhibition of the corresponding channel at the proximal renal tubules, which is responsible for reabsorbing most filtered glucose. Inhibiting this channel, it produces an osmotic effect without the proportional sodium loss seen with loop diuretics. Conventional therapies for SIAD often yield only modest improvements in serum sodium with response rates below 50%. Notably, 2 recent proof-of-concept studies demonstrated that adding a sodium-glucose cotransporter-2 inhibitor to fluid restriction resulted in a statistically significant increase in serum sodium…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.